Advertisement

Acta Biologica Hungarica

, Volume 65, Issue 4, pp 369–378 | Cite as

The Effects of Pituitary Adenylate Cyclase Activating Polypeptide in Renal Ischemia/Reperfusion

A Review
  • Eszter László
  • P. Kiss
  • Gabriella Horváth
  • P. Szakály
  • Andrea Tamás
  • Dóra ReglődiEmail author
Article

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP) is a multifunctional neuropeptide occurring in the nervous system as well as in the peripheral organs. Beneficial action of PACAP has been shown in different pathological processes. The strong protective effects of the peptide are probably due to its complex modulatory actions in antiapoptotic, anti-inflammatory and antioxidant pathways. In the kidney, PACAP is protective in models of diabetic nephropathy, myeloma kidney injury, cisplatin-, gentamycinand cyclosporin-induced damages. Numerous studies have been published describing the protective effect of this peptide in renal ischemia/reperfusion. The present review focuses on the ischemia/reperfusion-induced kidney injury and gives a brief summary about the results published in this area.

Keywords

Kidney ischemia/reperfusion PACAP renoprotection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

Support by TAMOP 4.2.4.A/2-11-1-2012-0001 ‘National Excellence Program’, PTE-MTA Lendület Program, Arimura Foundation, OTKA K104984, OTKA PD 109644, Bolyai Scholarship, TÁMOP 4.2.2.A-11/1/KONV-2012-0024.

References

  1. 1.
    Arimura, A., Somogyvári-Vigh, A., Miyata, A., Mizuno, K., Coy, D. H., Kitada, C. (1991) Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129, 2787–2789.PubMedGoogle Scholar
  2. 2.
    Arimura, A., Li, M., Batuman, V. (2006) Potential protective action of pituitary adenylate cyclase activating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107, 661–668.PubMedGoogle Scholar
  3. 3.
    Arimura, A., Li, M., Batuman, V. (2006) Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38. Ann. NY Acad. Sci. 1070, 14.Google Scholar
  4. 4.
    Atlasz, T., Babai, N., Kiss, P., Reglodi, D., Tamas, A., Szabadfi, K., Toth, G., Hegyi, O., Lubics, A., Gabriel, R. (2007) Pituitary adenylate cyclase activating polypeptide is protective in bilateral carotid occlusion-induced retinal lesion in rats. Gen. Comp. 153, 108–114.Google Scholar
  5. 5.
    Bánki, E., Degrell, P., Kiss, P., Kovacs, K., Kemeny, A., Csanaky, K., Duh, A., Nagy, D., Toth, G., Tamas, A., Reglodi, D. (2013) Effect of PACAP treatment on kidney morphology and cytokine expression in rat diabetic nephropathy. Peptides 42, 125–130.PubMedGoogle Scholar
  6. 6.
    Basile, D. P., Martin, D. R., Hammerman, M. R. (1998) Extracellular matrix-related genes in kidney after ischemic injury: potential role for TGF-beta in repair. Am. J. Physiol. 275, 894–903.Google Scholar
  7. 7.
    Brubel, R., Horvath, G., Reglodi, D., Lubics, A., Tamas, A., Kiss, P., Laszlo, E., Nemeth, J., Mark, L., Szakaly, P. (2011) Presence of pituitary adenylate cyclase activating polypeptide and its type I receptor in the rat kidney. Transplant. Proc. 43, 1297–1299.PubMedGoogle Scholar
  8. 8.
    Ferencz, A., Racz, B,. Tamas, A., Reglodi, D., Lubics, A., Nemeth, J., Nedvig, K., Kalmar-Nagy, K., Horvath, O. P., Weber, G., Roth, E. (2009) Influence of PACAP on oxidative stress and tissue injury following small bowel autotransplantation. J. Mol. Neurosci. 37, 168–176.PubMedGoogle Scholar
  9. 9.
    Ferencz, A., Kiss, P., Weber, Gy., Helyes, Z., Shintani, N., Baba, A., Reglodi, D. (2010) Comparison of intestinal warm ischemic injury in PACAP knockout and wild-type mice. J. Mol. Neurosci. 42, 435–442.PubMedGoogle Scholar
  10. 10.
    Ferencz, A., Weber, Gy., Helyes, Z., Hashimoto, H., Baba, A., Reglodi, D. (2010) Presence of endogenous PACAP-38 ameliorated intestinal cold preservation tissue injury. J. Mol. Neurosci. 42, 428–434.PubMedGoogle Scholar
  11. 11.
    Gardiner, S. M., Rakhit, T., Kemp, P. A., March, J. E., Bennett, T. (1994) Regional haemodynamic responses to pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in conscious rats. Br. J. Pharmacol. 111, 589–597.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Harmar, A. J., Sheward, W. J., Morrison, C. F., Waser, B., Gugger, M., Reubi, J. C. (2004) Distribution of the VPAC 2 receptor in peripheral tissues of the mouse. Endocrinology 145, 1203–1210.PubMedGoogle Scholar
  13. 13.
    Hautmann, M., Friis, U. G., Desch, M., Todorov, V., Castrop, H., Segerer, F., Otto, C., Schutz, G., Schweda, F. (2007) Pituitary adenylate cyclase activating polypeptide stimulates renin secretion via activation of PAC 1 receptors. J. Am. Soc. Nephrol. 18, 1150–1156.PubMedGoogle Scholar
  14. 14.
    Horvath, G., Mark, L., Brubel, R., Szakaly, P., Racz, B., Kiss, P., Tamas, A., Helyes, Z., Lubics, A., Hashimoto, H., Baba, A., Shintani, S., Furjes, G., Nemeth, J., Reglodi, D. (2010) Mice deficient in pituitary adenylate cyclase activating polypeptide display increased sensitivity to renal oxidative stress in vitro. Neurosci. Lett. 469, 70–74.PubMedGoogle Scholar
  15. 15.
    Horvath, G., Racz, B., Reglodi, D., Kovacs, K., Kiss, P., Gallyas Jr., F., Bognar, Z., Szabo, A., Magyarlaki, T., Laszlo, E., Lubics, A., Tamas, A., Toth, G., Szakaly, P. (2010) Effects of PACAP on mitochondrial apoptotic pathways and cytokine expression in rats subjected to renal ischemia/reperfusion. J. Mol. Neurosci. 42, 411–418.PubMedGoogle Scholar
  16. 16.
    Horvath, G., Racz, B., Szakaly, P., Kiss, P., Laszlo, E., Hau, L., Tamas, A., Helyes, Z., Lubics, A., Hashimoto, H., Baba, A., Reglodi, D. (2010) Mice deficient in neuropeptide PACAP demonstrate increased sensitivity to in vitro kidney hypoxia. Transplant. Proc. 42, 2293–2295.PubMedGoogle Scholar
  17. 17.
    Horvath, G., Brubel, R., Kovacs, K., Reglodi, D., Opper, B., Ferencz, A., Szakaly, P., Laszlo, E., Hau, L., Kiss, P., Tamas, A., Racz, B. (2011) Effects of PACAP on oxidative stress-induced cell death in primary rat kidney and human hepatocyte cell cultures. J. Mol. Neurosci. 43, 67–75.PubMedGoogle Scholar
  18. 18.
    Jain, S., Bicknell, G. R., Nicholson, M. L. (2000) Molecular changes in extracellular matrix turnover after renal ischemia-reperfusion injury. Br. J. Surg. 87, 1188–1192.PubMedGoogle Scholar
  19. 19.
    Jang, H. R., Gandolfo, M. T., Ko, G. J., Satpute, S. R., Racusen, L., Rabb, H. (2010) B cells limit repair after ischemic acute kindey injury. J. Am. Soc. Nephrol. 21, 654–665.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Ji, H., Zhang, Y., Shen, X. D., Gao, F., Huang, C. Y., Abad, C., Busuttil, R. W., Waschek, J. A., Kupiec-Weglinski, J. W. (2013) Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMP-PKA pathway. Hepatology 57, 1225–1237.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Khan, A. M., Li, M., Brant, E., Maderdrut, J. L., Majid, D. S. A., Simon, E. E., Batuman, V. (2011) Renoprotection with pituitary adenylate cyclase activating polypeptide in cyclosporin A-induced nephrotoxicity. J. Invest. Med. 59, 793–802.Google Scholar
  22. 22.
    Khan, A. M., Li, M., Abdulnour-Nakhoul, S., Maderdrut, J. L., Simon, E. E., Batuman, V. (2012) Delayed administration of pituitary adenylate cyclase-activating polypeptide 38 ameliorates renal ischemia/reperfusion injury in mice by modulating Toll-like receptors. Peptides 38, 395–403.PubMedGoogle Scholar
  23. 23.
    Laburthe, M., Couvineau, A., Tan, V. (2007) Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 28, 1631–1639.PubMedGoogle Scholar
  24. 24.
    Lam, H. C., Takahashi, K., Ghatei, M. A., Kanse, S. M., Polak, J. M., Bloom, S. R. (1990) Binding sites of a novel neuropeptide pituitary adenylate cyclase activating polypeptide in the rat brain and lung. Eur. J. Biochem. 193, 725–729.PubMedGoogle Scholar
  25. 25.
    Li, M., Cortez, S., Nakamachi, T., Batuman, V., Arimura, A. (2006) Pituitary adenylate cyclase activating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells. Cancer Res. 66, 8796–8803.Google Scholar
  26. 26.
    Li, M., Maderdrut, J. L., Lertora, J. J. L., Batuman, V. (2007) Intravenous infusion of pituitary adenylate cyclase activating polypeptide (PACAP ) in a patient with multiple myeloma and myeloma kidney: a case study. Peptides 28, 1891–1895.PubMedGoogle Scholar
  27. 27.
    Li, M., Maderdrut, J. L., Lertora, J. J. L., Arimura, A., Batuman, V. (2008) Renoprotection by pituitary adenylate cyclase activating polypeptide in multiple myeloma and other kidney diseases. Regul. Pept. 145, 24–32.PubMedGoogle Scholar
  28. 28.
    Li, M., Balamuthusamy, S., Khan, A. M., Maderdrut, J. L., Simon, E. E., Batuman, V. (2010) Pituitary adenylate cyclase activating polypeptide ameliorates cisplatin-induced acute kidney injury. Peptides 31, 592–602.Google Scholar
  29. 29.
    Li, M., Khan, A. M., Maderdrut, J. L., Simon, E. E., Batuman, V. (2010) The effect of PACAP 38 on MyD88-mediated signal transduction in ischemia/hypoxia-induced acute kidney injury. Am. J. Nephrol. 32, 522–532.PubMedGoogle Scholar
  30. 30.
    Li, M., Balamuthusamy, S., Khan, A. M., Maderdrut, J. L., Simon, E. E., Batuman, V. (2011) Pituitary adenylate cyclase activating polypeptide prevents cisplatin-induced renal failure. J. Mol. Neurosci. 43, 58–66.PubMedGoogle Scholar
  31. 31.
    Menger, M. D., Vollmar, B. (2007) Pathomechanisms of ischemia-reperfusion injury as the basis for novel preventive strategies: is it time for the introduction of pleiotropic compounds? Transplant. Proc. 39, 485–488.PubMedGoogle Scholar
  32. 32.
    Reglodi, D., Somogyvari-Vigh, A., Vigh, S., Kozicz, T., Arimura, A. (2000) Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 31, 1411–1417.Google Scholar
  33. 33.
    Reglodi, D., Kiss, P., Lubics, A., Tamas, A. (2011) Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr. Pharm. Des. 17, 962–972.Google Scholar
  34. 34.
    Reglodi, D., Kiss, P., Horvath, G, Lubics, A., Laszlo, E., Tamas, A., Racz, B., Szakaly, P. (2012) Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney. Neuropeptides 46, 61–70.PubMedGoogle Scholar
  35. 35.
    Reglodi, D., Kiss, P., Szabadfi, K., Atlasz, T., Gabriel, R., Horvath, G., Szakaly, P., Sandor, B., Lubics, A., Laszlo, E., Farkas, J., Matkovits, A., Brubel, R., Hashimoto, H., Ferencz, A., Vincze, A., Helyes, Z., Welke, L., Lakatos, A., Tamas, A. (2012) PACAP is an endogenous protective factor-insights from PACAP-deficient mice. J. Mol. Neurosci. 48, 482–492.Google Scholar
  36. 36.
    Reubi, J. C. (2000) In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann. NY Acad. Sci. 921, 1–25.PubMedGoogle Scholar
  37. 37.
    Reubi, J. C., Laderach, U., Waser, B., Gebbers, J. O., Robberecht, P., Laissue, J. A. (2000) Vasoactive intestinal peptide/pituitary adenylate cyclase activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 60, 3105–3112.PubMedGoogle Scholar
  38. 38.
    Riera, M., Torras, J., Cruzado, J. M., Lloberas, N., Liron, J., Herrero, I., Navarro, M. A., Grinyo, J. M. (2001) The enhancement of endogenous cAMP with pituitary adenylate cyclase activating polypeptide protects rat kidney against ischemia through the modulation of inflammatory response. Transplantation 72, 1217–1223.PubMedGoogle Scholar
  39. 39.
    Roth, E., Weber, G., Kiss, P., Horvath, G., Toth, G., Gasz, B., Ferencz, A., Gallyas, F. Jr., Reglodi, D., Racz, B. (2009) Effects of PACAP and preconditioning against ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro. Ann. NY Acad. Sci. 1163, 512–516.PubMedGoogle Scholar
  40. 40.
    Saikumar, P., Venkatachalam, M. A. (2003) Role of apoptosis in hypoxic/ischemic damage in the kidney. Semin Nephrol. 23, 511–521.PubMedGoogle Scholar
  41. 41.
    Seaborn, T., Masmoudi-Kouli, O., Fournier, A., Vaudry, H., Vaudry, D. (2011) Protective effects of pituitary adenylate cyclase-activating polypeptide (PACAP ) against apoptosis. Curr. Pharm. Des. 17, 204–214.PubMedGoogle Scholar
  42. 42.
    Somogyvari-Vigh, A., Reglodi, D. (2004) Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr. Pharm. Des. 10, 2861–2889.PubMedGoogle Scholar
  43. 43.
    Szabadfi, K., Atlasz, T., Kiss, P., Danyadi, B., Tamas, A., Helyes, Z., Hashimoto, H., Shintani, N., Baba, A., Toth, G., Gabriel, R., Reglodi, D. (2012) Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivo. Neurotox. Res. 21, 41–48.PubMedGoogle Scholar
  44. 44.
    Szakaly, P., Kiss, P., Lubics, A., Magyarlaki, T., Tamas, A., Racz, B., Lengvari, I., Toth, G., Reglodi, D. (2008) Effects of PACAP on survival and renal morphology in rats subjected to renal ischemia–reperfusion. J. Mol. Neurosci. 36, 89–96.PubMedGoogle Scholar
  45. 45.
    Szakaly, P., Horvath, G., Kiss, P., Laszlo, E., Farkas, J., Furjes, G., Nemeth, J., Reglodi, D. (2010) Changes in pituitary adenylate cyclase activating polypeptide following renal ischemia–reperfusion in rats. Transplant. Proc. 42, 2283–2286.PubMedGoogle Scholar
  46. 46.
    Szakaly, P., Laszlo, E., Kovacs, K., Racz, B., Horvath, G., Ferencz, A., Lubics, A., Kiss, P., Tamas, A., Brubel, R., Opper, B., Baba, A., Hashimoto, H., Farkas, J., Matkovits, A., Magyarlaki, T., Helyes, Zs., Reglodi, D. (2011) Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury. Neuropeptides 45, 113–121.PubMedGoogle Scholar
  47. 47.
    Tamas, A., Reglodi, D., Farkas, O., Kovesdi, E., Pal, J., Povlishock, J. T., Schwarcz, A., Czeiter, E., Szanto, Z., Doczi, T., Buki, A., Bukovics, P. (2012) Effect of PACAP in central and peripheral nerve injuries. Int. J. Mol. Sci. 13, 8430–8448.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Uchida, D., Arimura, A., Somogyvari-Vigh, A., Shioda, S., Banks, W. A. (1996) Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res. 736, 280–286.PubMedGoogle Scholar
  49. 49.
    Vannay, A., Fekete, A., Langer, R., Toth, T., Sziksz, E., Vasarhelyi, B., Szabo, A. J., Losonczy, G., Adori, C., Gal, A., Tulassay, T., Szabo, A. (2009) Dehydroepiandrosterone pretreatment alters the ischemia/reperfusion-induced VEGF, IL-1, and IL-6 gene expression in acute renal failure. Kidney Blood Press. Res. 32, 175–184.PubMedGoogle Scholar
  50. 50.
    Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., Fournier, A., Chow, B. K., Hashimoto, H., Galas, L., Vaudry, H. (2009) Pituitary adenylate cyclase activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 61, 283–357.PubMedGoogle Scholar
  51. 51.
    Wei, Y., Mojsov, S. (1996) Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology. J. Neuroendocrinol. 8, 811–817.PubMedGoogle Scholar
  52. 52.
    Zhou, X., Rodriguez, W. I., Casillas, R. A., Ma, V., Tam, J., Hu, Z., Lelievre, V., Chao, A., Waschek, J. A. (1999) Axotomy-induced changes in pituitary adenylate cyclase activating polypeptide (PACAP ) and PACAP receptor gene expression in the adult rat facial motor nucleus. J. Neurosci. Res. 57, 953–961.PubMedGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest 2014

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Eszter László
    • 1
  • P. Kiss
    • 1
  • Gabriella Horváth
    • 1
  • P. Szakály
    • 2
  • Andrea Tamás
    • 1
  • Dóra Reglődi
    • 1
    Email author
  1. 1.Department of AnatomyPTE-MTA PACAP “Lendület” Research TeamHungary
  2. 2.Department of SurgeryUniversity of PécsPécsHungary

Personalised recommendations